| Company/Division name | Ansa Biotechnologies, Inc. |
| Type of work | Manufacturing |
| If manufacturing, is the company an OEM? | Yes |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2020 |
| Year reshoring implemented or to be implemented: | 2020 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 7.9 |
| City reshored to: | Berkeley |
| State(s) reshored to: | CA |
| If relevant, work nearshored to: | - |
| Product(s) reshored | synthetic DNA manufacturing, engineering biology |
| What domestic positive factors made reshoring more attractive? | Lead time/Time to market, vet clients for biosecurity |
